The US bladder cancer market is estimated to grow modestly at a CAGR of around 9.7% during the forecast period. The US contributes significantly to the growth of the bladder cancer treatment market in North America. The increasing aging population across the country is augmenting the growth of the market. According to the American Cancer Society, bladder cancer occurs mainly in older people, with an average age at the time of diagnosis being 73 years. US Census Bureau estimated that people aged over 65 years represent around 15% of the total population of the country in 2015. This share is further estimated to reach 21% by 2030 and 24% by 2060.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/us-bladder-cancer-market

Bladder cancer is the fourth most common cancer in men; however, it is less common in women. American Cancer Society has provided bladder cancer statistics for 2019 in the US. The society estimates that around 80,470 new cases of bladder cancer will be diagnosed in the country, of which 61,700 will be in men and 18,770 will be in women. This prevalence of bladder cancer will lead to mortalities across the country. The US consists of some of the key players of the bladder cancer market such as Merck & Co, Inc., Pfizer, Inc., and Spectrum Pharmaceuticals, Inc., which further augments the growth of the market in the country.

A Full Report of US Bladder Cancer Market is Available at: https://www.omrglobal.com/industry-reports/us-bladder-cancer-market

US bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.

Market Segmentation

US Bladder Cancer Market by Cancer Type

Transitional Cell Bladder Cancer/ Urothelial Carcinoma
Squamous Cell Bladder Cancer
Adenocarcinoma
Others (Sarcomas, Carcinoma in Situ)
US Bladder Cancer Market by Diagnosis

Cystoscopy
Biopsy
Urinalysis
Urine Cytology
Intravenous Pyelogram (IVP)
Others (Biomarkers)
US Bladder Cancer Market by Treatment

Surgery
Chemotherapy
Immunotherapy
Radiation Therapy
Others (Targeted Therapy)
Company Profiles

Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Co.
Eli Lilly and Co.
EMD Serono, Inc.
F. Hoffmann-La Roche Ltd.
Genentech Inc.
GlaxoSmithKline Plc
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Pfizer Inc.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/us-bladder-cancer-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404